All In Biotech

Drug Trial Radar · NCT05408845

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

A Phase II Trial of HER2-Targeted Therapies for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 146 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

146

Planned (sponsor's estimate)

Start

Mar 3, 2023

Primary completion

Jul 31, 2028

Study completion Jul 31, 2033

Sponsor

Lead sponsor
NRG OncologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Jun 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial compares the effect of usual treatment of docetaxel chemotherapy plus trastuzumab, to ado-emtansine (T-DM1) in patients with HER2-positive salivary gland cancer that has come back (recurrent), that has spread from where it first started (primary site) to other places in the body, or cannot be removed by surgery (unresectable). This trial is also testing how well trastuzumab deruxtecan works in treating patients with HER2-low recurrent or metastatic salivary gland cancer. Trastuzumab is a form of targeted therapy because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by body's immune system. Trastuzumab emtansine contains trastuzumab, linked to a chemotherapy drug called emtansine. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers emtansine to kill them. Trastuzumab deruxtecan is a monoclonal antibody called trastuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors and delivers deruxtecan to kill them. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Trastuzumab emtansine may work better compared to usual treatment of chemotherapy with docetaxel and trastuzumab or trastuzumab deruxtecan in treating patients with recurrent, metastatic or unresectable salivary gland cancer.

Conditions

  • Metastatic Salivary Gland Carcinoma
  • Recurrent Salivary Gland Carcinoma
  • Stage III Major Salivary Gland Cancer AJCC v8
  • Stage IV Major Salivary Gland Cancer AJCC v8
  • Unresectable Salivary Gland Carcinoma

Interventions

  • Biopsy ProcedureProcedure

    Undergo a biopsy

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Computed TomographyProcedure

    Undergo a CT scan

  • DocetaxelDrug

    Given IV

  • Echocardiography TestProcedure

    Undergo ECHO

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Multigated Acquisition ScanProcedure

    Undergo MUGA

  • Questionnaire AdministrationOther

    Ancillary studies

  • TrastuzumabBiological

    Given IV

  • Trastuzumab DeruxtecanBiological

    Given IV

  • Trastuzumab EmtansineBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS) (HER2-Positive Cohort)Time frame: From randomization to disease progression or death due to any cause, whichever occurs first, assessed up to 5 years
  2. Objective response rate (ORR) (HER2-Low Expressing Cohort)Time frame: From the start of treatment up to a year or until the progression of disease, unacceptable toxicity, physician discretion to discontinue treatment, or patient withdrawal of consent, whichever occurs first.), assessed up to 5 years

Locations

154 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama · Active not recruiting

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Active not recruiting

  • Kaiser Permanente Dublin

    Dublin, California · Recruiting

  • Kaiser Permanente-Fremont

    Fremont, California · Recruiting

  • Kaiser Permanente Fresno Orchard Plaza

    Fresno, California · Recruiting

  • Kaiser Permanente-Fresno

    Fresno, California · Recruiting

  • City of Hope at Irvine Lennar

    Irvine, California · Active not recruiting

  • Kaiser Permanente- Modesto MOB II

    Modesto, California · Recruiting

  • Kaiser Permanente-Modesto

    Modesto, California · Recruiting

  • Kaiser Permanente-Oakland

    Oakland, California · Recruiting

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California · Recruiting

  • Kaiser Permanente-Roseville

    Roseville, California · Recruiting

  • Kaiser Permanente Downtown Commons

    Sacramento, California · Recruiting

  • Kaiser Permanente-South Sacramento

    Sacramento, California · Recruiting

  • Kaiser Permanente-San Francisco

    San Francisco, California · Recruiting

  • UCSF Medical Center-Mission Bay

    San Francisco, California · Suspended

  • Kaiser Permanente-Santa Teresa-San Jose

    San Jose, California · Recruiting

  • Kaiser Permanente San Leandro

    San Leandro, California · Recruiting

  • Kaiser San Rafael-Gallinas

    San Rafael, California · Recruiting

  • Kaiser Permanente Medical Center - Santa Clara

    Santa Clara, California · Recruiting

  • Kaiser Permanente-Santa Rosa

    Santa Rosa, California · Recruiting

  • Kaiser Permanente-South San Francisco

    South San Francisco, California · Recruiting

  • Kaiser Permanente-Vallejo

    Vallejo, California · Recruiting

  • Kaiser Permanente-Walnut Creek

    Walnut Creek, California · Recruiting

  • UCHealth University of Colorado Hospital

    Aurora, Colorado · Recruiting

  • UCHealth Highlands Ranch Hospital

    Highlands Ranch, Colorado · Recruiting

  • Miami Cancer Institute

    Miami, Florida · Recruiting

  • Emory University Hospital Midtown

    Atlanta, Georgia · Recruiting

  • Kaiser Permanente Moanalua Medical Center

    Honolulu, Hawaii · Recruiting

  • Saint Luke's Cancer Institute - Boise

    Boise, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Fruitland

    Fruitland, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Meridian

    Meridian, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Nampa

    Nampa, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Twin Falls

    Twin Falls, Idaho · Recruiting

  • Carle at The Riverfront

    Danville, Illinois · Recruiting

  • Carle Physician Group-Effingham

    Effingham, Illinois · Recruiting

  • Carle Physician Group-Mattoon/Charleston

    Mattoon, Illinois · Recruiting

  • Memorial Hospital East

    Shiloh, Illinois · Recruiting

  • Carle Cancer Center

    Urbana, Illinois · Recruiting

  • McFarland Clinic - Ames

    Ames, Iowa · Active not recruiting

Showing 40 of 154 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.